Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 6/2012

01-06-2012 | Head and Neck Oncology

The Determining Risk Factors for Treatment Outcomes in Patients with Squamous Cell Carcinoma of the Hard Palate

Authors: Fan-Yu Meng, MD, Jeng-Yuh Ko, MD, PhD, Pei-Jen Lou, MD, PhD, Cheng-Ping Wang, MD, Tsung-Lin Yang, MD, PhD, Chun-Hsiang Chang, MD, Yih-Leong Chang, MD, Tseng-Cheng Chen, MD

Published in: Annals of Surgical Oncology | Issue 6/2012

Login to get access

Abstract

Background

The determining risk factors for patients with squamous cell carcinoma of the hard palate are not well verified.

Methods

Medical records from our facility of all patients with squamous cell carcinoma of the hard palate receiving curative surgery between March 2003 and May 2009 were reviewed.

Results

Seventy-eight patients were enrolled in the study. The 5 year disease-free and overall survival rates were 49.8 and 49.7%, respectively. The 5 year disease-free and overall survival rates were statistically different between positive/close margins and negative margins (24.6% vs. 65.4%, P = 0.02; 20.1% vs. 63.1%, P = 0.001, respectively), with and without soft palate invasion (38.8% vs. 68.9%, P = 0.02; 27.4% vs. 77.5%, P = 0.001, respectively), and soft palate invasion patients with and without perineural invasion (10.4% vs. 52.8%, P = 0.02; 0% vs. 38.1%, P = 0.008, respectively). The rate of positive nodal metastasis for T3 and T4 tumors was 44%. For the tumor with soft palate invasion, the rate of positive nodal metastasis was 29%. After multivariate analyses, soft palate invasion and positive/close margins were the determining risk factors for disease-free and overall survival.

Conclusions

Soft palate invasion and positive/close margins were the determining risk factors for disease-free and overall survival in patients with squamous cell carcinoma of the hard palate. Elective neck dissection is suggested for advanced primary tumors (T3 or T4) or tumors with soft palate invasion.
Literature
1.
Liao CT, Chang JT, Wang HM, Ng SH, Hsueh C, Lee LY, et al. Analysis of risk factors of predictive local tumor control in oral cavity cancer. Ann Surg Oncol. 2008;15:915–22.PubMedCrossRef
2.
Liao CT, Wang HM, Chang JT, Ng SH, Hsueh C, Lee LY, et al. Analysis of risk factors for distant metastases in squamous cell carcinoma of the oral cavity. Cancer. 2007;110:1501–8.PubMedCrossRef
3.
Liao CT, Huang SF, Chen IH, Kang CJ, Lin CY, Fan KH, et al. Outcome analysis of patients with pN2 oral cavity cancer. Ann Surg Oncol. 2010;17:1118–26.PubMedCrossRef
4.
Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007;357:1705–15.PubMedCrossRef
5.
Kurita H, Nakanishi Y, Nishizawa R, Xiao T, Kamata T, Koike T, et al. Impact of different surgical margin conditions on local recurrence of oral squamous cell carcinoma. Oral Oncol. 2010;46:814–7.PubMedCrossRef
6.
Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007;357:1695–704.PubMedCrossRef
7.
Mashberg A, Meyers H. Anatomical site and size of 222 early asymptomatic oral squamous cell carcinomas: a continuing prospective study of oral cancer II. Cancer. 1976;37:2149–57.PubMedCrossRef
8.
Lin HW, Bhattacharyya N. Survival impact of nodal disease in hard palate and maxillary alveolus cancer. Laryngoscope. 2009;119:312–5.PubMedCrossRef
9.
Helliwell T, Woolgar JA. Standards and minimum datasets for reporting cancers. Dataset for histopathologic reports on head and neck carcinomas and salivary neoplasms. 2nd ed. London: Royal College of Pathologists; 2005.
10.
Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, eds. AJCC cancer staging manual. 6th ed. New York: Springer-Verlag; 2002.
11.
Ferlito A, Rinaldo A, Silver CE, Gourin CG, Shah JP, Clayman GL, et al. Elective and therapeutic selective ND. Oral Oncol. 2006;42:14–25.PubMedCrossRef
12.
13.
Wei WI, Ferlito A, Rinaldo A, Gourin CG, Lowry J, Ho WK, et al. Management of the N0 neck—reference or preference. Oral Oncol. 2006;42:115–22.PubMedCrossRef
14.
15.
Morris LG, Patel SG, Shah JP, Ganly I. High rates of regional failure in squamous cell carcinoma of the hard palate and palatal alveolus. Head Neck. 2011;33:824–30.PubMedCrossRef
16.
Beltramini GA, Massarelli O, Demarchi M, Copelli C, Cassoni A, Valentini V, et al. Is neck dissection needed in squamous-cell carcinoma of the maxillary gingiva, alveolus, and hard palate? A multicentre Italian study of 65 cases and literature review. Oral Oncol. 2011 [Epub ahead of print].
17.
Olzowy B, Tsalemchuk Y, Schotten KJ, Reichel O, Harréus U. Frequency of bilateral cervical metastases in oropharyngeal squamous cell carcinoma: a retrospective analysis of 352 cases after bilateral ND. Head Neck. 2011;33:239–43.PubMedCrossRef
18.
Mendenhall WM, Parsons JT, Mendenhall NP, Brant TA, Stringer SP, Cassisi NJ, et al. Carcinoma of the skin of the head and neck with perineural invasion. Head Neck. 1989;11:301–8.PubMedCrossRef
19.
Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefèbvre JL, Greiner RH, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350:1945–52.PubMedCrossRef
20.
Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004;350:1937–44.PubMedCrossRef
21.
Maddox WA, Urist MM. Histopathological prognostic factors of certain primary oral cavity cancers. Oncology (Williston Park). 1990;4:39–42.
Metadata
Title
The Determining Risk Factors for Treatment Outcomes in Patients with Squamous Cell Carcinoma of the Hard Palate
Authors
Fan-Yu Meng, MD
Jeng-Yuh Ko, MD, PhD
Pei-Jen Lou, MD, PhD
Cheng-Ping Wang, MD
Tsung-Lin Yang, MD, PhD
Chun-Hsiang Chang, MD
Yih-Leong Chang, MD
Tseng-Cheng Chen, MD
Publication date
01-06-2012
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 6/2012
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-011-2214-1

Other articles of this Issue 6/2012

Annals of Surgical Oncology 6/2012 Go to the issue

Risk Assessment and Genetic Testing for Hereditary Breast Cancer

Hereditary Breast Cancer: Practical Pursuit for Clinical Translation

Colorectal Cancer

Ex Vivo Evaluation of Preoperatively Treated Rectal Cancer Specimens of Patients Undergoing Radical Resection

Breast Oncology

Paget’s Disease as a Local Recurrence after Nipple-Sparing Mastectomy: Clinical Presentation, Treatment, Outcome, and Risk Factor Analysis

Gastrointestinal Oncology

Duodenal Adenocarcinoma: Clinicopathologic Analysis and Implications for Treatment

Thoracic Oncology

Cytokeratin 7 is a Predictive Marker for Survival in Patients with Esophageal Squamous Cell Carcinoma

Hepatobiliary Tumors

Predictors for Microinvasion of Small Hepatocellular Carcinoma ≤2 cm